Načítá se...
The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
Treatment with empagliflozin, an inhibitor of the sodium/glucose cotransporter 2 (SGLT2), is associated with slower progression of diabetic kidney disease. In this analysis, we explored the hypothesis that empagliflozin may have an impact on urinary peptides associated with chronic kidney disease (C...
Uloženo v:
| Vydáno v: | PLoS One |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Public Library of Science
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5662219/ https://ncbi.nlm.nih.gov/pubmed/29084249 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0186910 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|